125 related articles for article (PubMed ID: 6648143)
21. Screening status, tumour subtype, and breast cancer survival: a national population-based analysis.
O'Brien KM; Mooney T; Fitzpatrick P; Sharp L
Breast Cancer Res Treat; 2018 Nov; 172(1):133-142. PubMed ID: 30006795
[TBL] [Abstract][Full Text] [Related]
22. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years.
Miller AB; Baines CJ; To T; Wall C
CMAJ; 1992 Nov; 147(10):1477-88. PubMed ID: 1423088
[TBL] [Abstract][Full Text] [Related]
23. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival.
Duffy SW; Nagtegaal ID; Wallis M; Cafferty FH; Houssami N; Warwick J; Allgood PC; Kearins O; Tappenden N; O'Sullivan E; Lawrence G
Am J Epidemiol; 2008 Jul; 168(1):98-104. PubMed ID: 18504245
[TBL] [Abstract][Full Text] [Related]
24. Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data.
Swedish Organised Service Screening Evaluation Group
Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):45-51. PubMed ID: 16434585
[TBL] [Abstract][Full Text] [Related]
25. The Mayo Lung Cohort: a regression analysis focusing on lung cancer incidence and mortality.
Strauss GM
J Clin Oncol; 2002 Apr; 20(8):1973-83. PubMed ID: 11956255
[TBL] [Abstract][Full Text] [Related]
26. The effects of early treatment, lead time and length bias on the mortality experienced by cases detected by screening.
Morrison AS
Int J Epidemiol; 1982 Sep; 11(3):261-7. PubMed ID: 7129740
[TBL] [Abstract][Full Text] [Related]
27. Impact of mammographic screening on ethnic and socioeconomic inequities in breast cancer stage at diagnosis and survival in New Zealand: a cohort study.
Seneviratne S; Campbell I; Scott N; Shirley R; Lawrenson R
BMC Public Health; 2015 Jan; 15():46. PubMed ID: 25637343
[TBL] [Abstract][Full Text] [Related]
28. Statistical power in breast cancer screening trials and mortality reduction among women 40-49 years of age with particular emphasis on the National Breast Screening Study of Canada.
Kopans DB; Halpern E; Hulka CA
Cancer; 1994 Aug; 74(4):1196-203. PubMed ID: 8055437
[No Abstract] [Full Text] [Related]
29. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
Hristova L; Hakama M
Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
[TBL] [Abstract][Full Text] [Related]
30. A data-analytic approach for estimating lead time and screening benefit based on survival curves in randomized cancer screening trials.
Kafadar K; Prorok PC
Stat Med; 1994 Mar 15-Apr 15; 13(5-7):569-86. PubMed ID: 8023036
[TBL] [Abstract][Full Text] [Related]
31. Age-specific effectiveness of the Nijmegen population-based breast cancer-screening program: assessment of early indicators of screening effectiveness.
Peer PG; Holland R; Hendriks JH; Mravunac M; Verbeek AL
J Natl Cancer Inst; 1994 Mar; 86(6):436-41. PubMed ID: 8120918
[TBL] [Abstract][Full Text] [Related]
32. The impact of mammographic breast cancer screening in Singapore: a comparison between screen-detected and symptomatic women.
Wang WV; Tan SM; Chow WL
Asian Pac J Cancer Prev; 2011; 12(10):2735-40. PubMed ID: 22320984
[TBL] [Abstract][Full Text] [Related]
33. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years.
Miller AB; Baines CJ; To T; Wall C
CMAJ; 1992 Nov; 147(10):1459-76. PubMed ID: 1423087
[TBL] [Abstract][Full Text] [Related]
34. A reality check for overdiagnosis estimates associated with breast cancer screening.
Etzioni R; Xia J; Hubbard R; Weiss NS; Gulati R
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25362701
[TBL] [Abstract][Full Text] [Related]
35. Obligate Overdiagnosis Due to Mammographic Screening: A Direct Estimate for U.S. Women.
Hendrick RE
Radiology; 2018 May; 287(2):391-397. PubMed ID: 29267146
[TBL] [Abstract][Full Text] [Related]
36. The Gothenburg Breast Cancer Screening Trial: preliminary results on breast cancer mortality for women aged 39-49.
Bjurstam N; Björneld L; Duffy SW; Smith TC; Cahlin E; Erikson O; Lingaas H; Mattsson J; Persson S; Rudenstam CM; Säwe-Söderberg J
J Natl Cancer Inst Monogr; 1997; (22):53-5. PubMed ID: 9709276
[TBL] [Abstract][Full Text] [Related]
37. Is routine mammography screening appropriate for women 40-49 years of age?
Miller AB
Am J Prev Med; 1991; 7(1):55-62. PubMed ID: 1867901
[TBL] [Abstract][Full Text] [Related]
38. Effect of length biased sampling of unobserved sojourn times on the survival distribution when disease is screen detected.
Kafadar K; Prorok PC
Stat Med; 2009 Jul; 28(16):2116-46. PubMed ID: 19424959
[TBL] [Abstract][Full Text] [Related]
39. Mass screening for breast cancer: comparison of the clinical stages and prognosis of breast cancer detected by mass screening and in out-patient clinics.
Ota J; Horino T; Taguchi T; Ishida T; Izuo M; Ogita M; Abe R; Watanabe H; Morimoto T; Itoh S
Jpn J Cancer Res; 1989 Nov; 80(11):1028-34. PubMed ID: 2514163
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
